Please login to the form below

Not currently logged in
Email:
Password:

Encysive launches Thelin for hypertension in Spain

US-based Encysive Pharmaceuticals has launched Thelin (sitaxentan) 100 mg tablets in Spain for the treatment of pulmonary arterial hypertension (PAH).

US-based Encysive Pharmaceuticals has launched Thelin (sitaxentan) 100 mg tablets in Spain for the treatment of pulmonary arterial hypertension (PAH).

Encysive won EU marketing authorisation for the product from the EU Commission in August 2006.

Thelin is the first marketed selective endothelin A receptor antagonist, and the first once-daily oral treatment available for patients with PAH. Encysive will sell the product through its Spanish marketing partner, Praxis Pharmaceutical.

Thelin is indicated for improving exercise capacity in PAH patients classified as World Health Organisation (WHO) functional class III. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease (CTD).

Encysive will successively launch Thelin in all 27 member states of the EU, as local government approval for reimbursement is obtained, says the firm.

George Cole, Encysive's CEO, said: "Through our marketing partnership with Praxis, we are able to immediately begin selling THELIN in Spain without the need to invest in a dedicated sales and marketing infrastructure."

30th September 2008

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Medscape Education Global

Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....

Latest intelligence

Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...
Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...